Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21702
Title: A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer.
Authors: Roberts, Matthew J;Papa, Nathan;Perera, Marlon;Scott, Susan;Teloken, Patrick E;Joshi, Andre;Vela, Ian;Pryor, David;Martin, Jarad;Woo, Henry
Affiliation: Department of Urology, Austin Health, Heidelberg, Victoria, Australia
Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, NSW, Australia
Princess Alexandra Hospital, Brisbane, Qld, Australia
Faculty of Medicine, University of Queensland, Brisbane, Qld, Australia
Nepean Urology Research Group, Kingswood, NSW, Australia
Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
Australian Prostate Cancer Research Centre, Queensland University of Technology, Brisbane, Qld, Australia
Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia
Calvary Mater Newcastle, Waratah, NSW, Australia
Issue Date: 5-Sep-2019
EDate: 2019
Citation: BJU international 2019; online first: 5 September
Abstract: To characterize national clinical practice trends in the treatment of prostate cancer (PCa) in Australia. Population-level data were extracted from existing Medicare Benefits Schedule data for radical prostatectomy (RP) and brachytherapy (2002-2016), as well as external beam radiotherapy (EBRT; 2012-2016). Treatment rates were calculated relative to whole and PCa populations among privately treated patients. Overall age-related and geographical trends were analysed. The use of RP and low-dose-rate (LDR) brachytherapy increased between 2002 and 2009, but subsequently decreased to 124 and 6.9 per 100 000 men, respectively, in 2016. More dramatic decreases were observed for men aged <65 years. From 2012, rates of RP (15% drop) and LDR brachytherapy (58% drop) decreased, while the use of EBRT remained steady, falling by 5% to 42 per 100 000 men in 2016. Overall treatment increased in the age group 75-84 years, with the rate of RP increasing by 108%. National claims data indicate there has been a reduction in PCa treatment since 2009, which is mostly attributable to a reduction in the treatment of younger patients and reduced use of brachytherapy. RP is most commonly used and its use is rising in men aged >65 years.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21702
DOI: 10.1111/bju.14773
ORCID: 0000-0003-0552-7402
0000-0002-3188-1803
0000-0002-1138-6389
0000-0003-1414-8228
0000-0002-5659-0893
0000-0003-2574-2476
0000-0002-4929-0278
0000-0003-4099-0339
PubMed URL: 31486575
Type: Journal Article
Subjects: #PCSM
#ProstateCancer
physicians
practice patterns
prostatectomy
prostatic neoplasms
radiotherapy
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.